Gain Therapeutics Inc (GANX)
2.60
+0.09
(+3.59%)
USD |
NASDAQ |
May 21, 10:31
Gain Therapeutics Enterprise Value: 33.16M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 33.16M |
| May 17, 2024 | 35.32M |
| May 16, 2024 | 36.41M |
| May 15, 2024 | 35.14M |
| May 14, 2024 | 30.09M |
| May 13, 2024 | 31.53M |
| May 10, 2024 | 33.16M |
| May 09, 2024 | 33.70M |
| May 08, 2024 | 36.23M |
| May 07, 2024 | 40.20M |
| May 06, 2024 | 39.30M |
| May 03, 2024 | 41.28M |
| May 02, 2024 | 40.74M |
| May 01, 2024 | 41.46M |
| April 30, 2024 | 40.74M |
| April 29, 2024 | 42.00M |
| April 26, 2024 | 42.54M |
| April 25, 2024 | 43.27M |
| April 24, 2024 | 45.40M |
| April 23, 2024 | 49.01M |
| April 22, 2024 | 45.04M |
| April 19, 2024 | 45.22M |
| April 18, 2024 | 44.68M |
| April 17, 2024 | 45.22M |
| April 16, 2024 | 44.86M |
| Date | Value |
|---|---|
| April 15, 2024 | 43.59M |
| April 12, 2024 | 44.68M |
| April 11, 2024 | 48.47M |
| April 10, 2024 | 48.10M |
| April 09, 2024 | 48.83M |
| April 08, 2024 | 49.73M |
| April 05, 2024 | 52.07M |
| April 04, 2024 | 52.43M |
| April 03, 2024 | 59.83M |
| April 02, 2024 | 58.03M |
| April 01, 2024 | 56.94M |
| March 28, 2024 | 44.92M |
| March 27, 2024 | 44.27M |
| March 26, 2024 | 45.41M |
| March 25, 2024 | 42.98M |
| March 22, 2024 | 49.63M |
| March 21, 2024 | 54.65M |
| March 20, 2024 | 52.87M |
| March 19, 2024 | 52.71M |
| March 18, 2024 | 54.49M |
| March 15, 2024 | 53.36M |
| March 14, 2024 | 53.19M |
| March 13, 2024 | 57.41M |
| March 12, 2024 | 57.74M |
| March 11, 2024 | 59.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.270M
Minimum
May 24 2022
159.36M
Maximum
Mar 30 2021
37.19M
Average
30.93M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 768.05B |
| Alpine Immune Sciences Inc | 4.151B |
| Outlook Therapeutics Inc | 183.59M |
| OptiNose Inc | 214.66M |
| Greenwich LifeSciences Inc | 161.46M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.014M |
| Total Expenses (Quarterly) | 4.378M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -57.69% |
| Normalized Earnings Yield | -62.29 |